Point Of Care Infectious Disease Testing Market to 2033

The Point Of Care Infectious Disease Diagnostics Testing Market delivers rapid, near-patient results for viral, bacterial, and parasitic infections. Base-year valuation is USD 13.4 billion in 2025, with a forecast of USD 16.6 billion by 2033 at a 2.7% CAGR. The broader Infectious Disease Diagnostics Market remains larger, but POC formats capture growing share in decentralized settings.

• North America leads with 38% of global revenue, supported by CLIA-waived tests and retail pharmacy networks.
• Lateral flow immunoassay dominates technology share at 41%, though molecular POC platforms grow faster at 4.1%.
• COVID-19 testing normalization removed excess demand, but influenza, RSV, and strep A volumes provide baseline replacement.
• Reimbursement pressure and low-cost antigen competition keep average selling prices flat to declining in mature markets.

The market is transitioning from pandemic-era surge capacity to integrated respiratory and STI testing. Hospital Point Of Care Testing Market demand is sustained by emergency departments and urgent care, while the Home Infectious Disease Testing Market expands through e-commerce and telehealth. The COVID-19 Rapid Test Market is no longer the primary growth engine; instead, multiplex panels and molecular point-of-care analyzers drive premium pricing. Nitrocellulose Membrane Market supply constraints and antibody sourcing remain operational risks. Overall, growth is steady rather than explosive, with 2.7% CAGR reflecting mature COVID-19 comparisons and persistent access gaps in low-income regions.

• Reimbursement alignment is the single largest determinant of POC adoption in the United States and Germany.
• CLIA waivers and IVDR classifications shape product timelines by 6–18 months.
• Molecular consolidation is expected as smaller lateral flow vendors face margin compression.
• Emerging markets offer volume growth, but price points below USD 2 per test limit profitability.

• Lateral Flow Immunoassay Market remains the revenue anchor, with 41% share and 2.4% CAGR; margins range 35–50% at scale but fall below 20% for commodity COVID-19 antigen tests.
• Molecular Diagnostics POC Market grows at 4.1%, led by Abbott ID NOW, Roche cobas Liat, and Cepheid GeneXpert; instruments carry higher ASPs but require lab-like infrastructure.
• HIV POC Testing Market is mature in donor-funded programs, with >60 million tests annually; growth depends on viral load POC expansion.
• Respiratory Syncytial Virus POC Market benefits from pediatric and geriatric testing guidelines; seasonality creates capacity spikes.
• Agglutination tests retain niche demand for syphilis and streptococcal infections due to low cost and no instrument requirement.

• Reagent rental models shift profitability from instrument sales to consumables, locking in recurring revenue.
• Molecular POC systems face competition from lab-developed tests and centralized high-throughput analyzers.
• Lateral flow vendors absorb higher nitrocellulose and antibody costs, with 10–15% gross margin erosion in 2023–2025.
• The COVID-19 Rapid Test Market left excess capacity, forcing plant consolidations and price declines.
• Multiplexing is the primary defense against commoditization, allowing USD 25–60 per test versus USD 5–15 for single-analyte antigen tests.

• COVID-19, influenza, and RSV represent >50% of respiratory POC test volume.
• HIV, HBV, and HCV POC testing remain concentrated in public health and NGO procurement.
• TB and drug-resistant TB POC is the fastest-growing disease niche, albeit from a small base.
• STI POC testing, including HSV and HPV, is expanding through self-collection and retail clinics.

• Hospitals account for 34% of POC infectious disease diagnostics revenue, driven by emergency and inpatient respiratory testing.
• Clinics and physician offices represent 28%, with rapid strep, influenza, and COVID-19 tests embedded in workflow.
• Home Infectious Disease Testing Market reached 21% share after COVID-19 normalized self-test habits.
• Assisted living facilities and laboratories split the remainder, with 9% and 8% respectively.

• The 2.7% CAGR masks divergent performance: molecular POC grows at 4.1% while agglutination expands at 1.8%.
• Antimicrobial resistance diagnostics represent a USD 1.2 billion incremental opportunity by 2033, but require clinical validation and stewardship integration.
• CLIA waivers for respiratory panels have expanded the addressable base by 15–20% since 2020.
• The Nitrocellulose Membrane Market is capacity-constrained; single-source dependence can delay strip production by 8–12 weeks.
• Reimbursement cuts in Europe and U.S. Medicare rate updates create 5–10% price erosion for commodity antigen tests.
• FDA EUA transitions and IVDR reclassification increase compliance costs by USD 200,000–USD 1 million per molecular platform.
• Hospitals face nursing shortages that favor simple, instrument-free tests over complex molecular workflows.
• Home Infectious Disease Testing Market growth depends on insurance coverage and HSA/FSA eligibility.

• Abbott: Broadest POC portfolio with BinaxNOW, ID NOW, and retail pharmacy distribution; ~20% share in U.S. rapid antigen.
• F. Hoffmann-La Roche Ltd.: cobas Liat drives molecular POC leadership; strong hospital lab integration.
• Siemens Healthineers: CLINITEST rapid tests and EPOC blood analysis; focuses on emergency and critical care.
• bioMérieux SA: BioFire FilmArray multiplex panels command premium pricing in hospital sepsis and respiratory testing.
• Thermo Fisher Scientific Inc.: Supplies PCR reagents, enzymes, and POC platforms; benefits from molecular diagnostics scale.
• Becton, Dickinson & Company: BD Veritor and specimen collection systems; leverages hospital distribution.
• Chembio Diagnostics Inc.: Specializes in HIV and COVID-19 lateral flow; dependent on public health procurement.
• Trinity Biotech: Rapid tests for infectious disease; cost-competitive in clinic and lab channels.
• Quest Diagnostics Incorporated: Reference laboratory with POC services; influences test utilization and reimbursement.
• Bio-Rad Laboratories Inc.: Quality controls and PCR systems; key supplier to lab and POC validations.
• Sight Diagnostics Ltd.: AI-enabled blood diagnostics; niche but expanding into infectious disease triage.
• GenePOC: Molecular POC platform for infectious disease; targets low-complexity hospital labs.
• Trivitron Healthcare: Low-cost POC assays; strong in India and other Asia-Pacific markets.
• OJ-Bio Ltd.: Biosensor POC platforms; focuses on connected home and clinic testing.
• Ortho Clinical Diagnostics: Immunoassay and transfusion medicine; challenger in hospital POC.

• Abbott (2024) expanded its rapid antigen portfolio to include multiplex influenza A/B and RSV, reinforcing its ~20% U.S. POC share.
• Roche (2025) partnered with digital health vendors to connect cobas Liat results directly to hospital EHRs, reducing turnaround documentation.
• bioMérieux (2024) launched a near-patient respiratory panel, targeting hospital emergency departments and urgent care.
• BD (2023) integrated BD Veritor with EHR systems, improving result capture for CLIA-waived sites.
• Quest Diagnostics (2025) acquired POC testing assets to serve retail and employer health channels.
• Chembio (2024) launched a multiplex HIV-syphilis lateral flow test, targeting donor-funded programs.
• Trivitron Healthcare (2025) signed an ASEAN distribution agreement for low-cost POC assays.
• Sight Diagnostics (2023) raised venture funding for AI-enabled triage, signaling interest in connected POC.

• Asia-Pacific is the fastest-growing region at 4.2% CAGR, led by India, China, and ASEAN. India's POC testing volume exceeded 800 million tests in 2024.
• North America remains the largest market at USD 5.1 billion, but growth is limited to 2.3% due to reimbursement maturity and COVID-19 normalization.
• Europe grows at 2.5%, with IVDR compliance shaping product portfolios and favoring larger vendors.
• South America and Middle East & Africa are smaller but benefit from global health funding for HIV, TB, and malaria POC testing.
• Regulatory stringency is highest in North America and Europe; Asia-Pacific and Africa offer faster registration but variable quality oversight.
• The Hospital Point Of Care Testing Market is most developed in North America, while the Home Infectious Disease Testing Market grows fastest in Asia-Pacific.

• Hospital Point Of Care Testing Market buyers prioritize <15 minute turnaround and sensitivity above 90% for respiratory pathogens.
• Clinics are highly price-elastic; a USD 2–5 difference per test can shift vendor selection.
• Home Infectious Disease Testing Market purchase behavior is driven by retail promotions and telehealth bundling.
• Assisted living facilities require staff-friendly devices and Medicare/Medicaid reimbursement clarity.
• Laboratories use POC for triage but confirm with central lab methods, creating dual-testing pathways.
• Digital purchasing habits increased post-2020; >40% of clinics now order POC tests through e-procurement platforms.
• Price elasticity varies: molecular POC is less elastic due to clinical necessity, while antigen tests are highly elastic.
• Vendor loyalty is moderate; supply reliability and lot-to-lot consistency are decisive during respiratory season.

• Average selling prices for lateral flow antigen tests declined from USD 12–20 in 2021 to USD 4–9 in 2025 in the COVID-19 Rapid Test Market.
• Molecular POC tests maintain ASPs of USD 25–60 due to multiplexing and closed-system reagent lock-in.
• Respiratory Syncytial Virus POC Market pricing is seasonal; winter demand allows 10–15% premium pricing.
• Nitrocellulose Membrane Market cost increases of 8–12% since 2022 have compressed lateral flow margins.
• Manufacturers with internal antibody production retain 5–8 percentage points higher gross margin than outsourced peers.
• Hospital Point Of Care Testing Market buyers use GPO contracts to demand 10–20% volume discounts.
• Home Infectious Disease Testing Market pricing is retail-driven; private-label tests pressure branded ASPs.
• Inflation in labor and logistics has raised total POC test costs by 6–9% from 2023 to 2025, limiting margin expansion despite steady volumes.

• 1. Technology
  • 1.1. Lateral Flow Immunoassay
  • 1.2. Agglutination Test
  • 1.3. Flow-through test/Immunoconcentration Assay
  • 1.4. Molecular Diagnostics
  • 1.5. Others
• 2. Disease
  • 2.1. HIV POC
  • 2.2. Clostridium Difficile POC
  • 2.3. HBV POC
  • 2.4. Pneumonia Or Streptococcus Associated Infections
  • 2.5. Respiratory Syncytial Virus (RSV) POC
  • 2.6. HPV POC
  • 2.7. Influenza/Flu POC
  • 2.8. HCV POC
  • 2.9. MRSA POC
  • 2.10. TB & Drug-resistant TB POC
  • 2.11. HSV POC
  • 2.12. COVID-19
  • 2.13. Other Infectious Diseases
• 3. End Use
  • 3.1. Clinics
  • 3.2. Hospitals
  • 3.3. Home
  • 3.4. Assisted Living Healthcare Facilities
  • 3.5. Laboratory

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific